AstraZeneca appoints Fante to head U.S.
Executive Summary
U.K drug maker names Rich Fante to U.S. President Nov. 13. Fante, a 13-year veteran of the firm, was most recently VP-brand strategy and portfolio operations, leading development and marketing for all AstraZeneca brands in the U.S. Fante takes the helm from Tony Zook, CEO of North America and head of global marketing, whose role was expanded in July to include oversight of MedImmune after CEO David Mott left the firm one year after AstraZeneca's $15.6 billion buyout (1"The Pink Sheet" DAILY, June 26, 2008)
You may also be interested in...
MedImmune’s CEO Stepping Down
AstraZeneca’s North American CEO Zook will assume responsibilities until a successor is hired.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.